Phase II Study of Avastin + Erbitux + Irinotecan as 2nd Line Treatment of Colorectal Cancer
Status:
Terminated
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
This phase II study will evaluate the efficacy of the combination of two monoclonal
antibodies (Avastin + Erbitux) with irinotecan, in patients with colorectal cancer progressed
after 1st line treatment with FOLFIRI Avastin or XELIRI Avastin.